The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of olanzapine combined with the standard triplet antiemetic therapy for cisplatin-based chemotherapy: A sub-analysis of a randomized, double-blind, placebo-controlled trial (J-FORCE).
 
Yukiyoshi Fujita
No Relationships to Disclose
 
Masakazu Abe
No Relationships to Disclose
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - CAC Croit Corporation; Japan Tobacco Inc; Kowa; Ono Pharmaceutical
Speakers' Bureau - Asahi Kasei; Daiichi Sankyo; Nipro Corporation; Takeda; Tsumura & Co.
Research Funding - 3H Clinical Trial; 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice; Eisai; Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka; Puravida Technologies (Inst); Senju Pharmaceutical; Welby (Inst)
 
Hiroki Ueda
No Relationships to Disclose
 
Koichi Kitagawa
No Relationships to Disclose
 
Jun Okamura
No Relationships to Disclose
 
Katsuya Hirano
Honoraria - AstraZeneca; Chugai Pharma; Nippon Boehringer Ingelheim; Ono Pharmaceutical
 
Yukio Sakata
No Relationships to Disclose
 
Hirotoshi Iihara
No Relationships to Disclose
 
Yasuhiro Shimada
Honoraria - Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical
Research Funding - MSD K.K (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Aoyama
No Relationships to Disclose
 
Kazuhiko Shibata
No Relationships to Disclose
 
Kensuke Hori
No Relationships to Disclose
 
Haruko Daga
Honoraria - Chugai/Roche; MSD Oncology; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai/Roche (Inst); Lilly (Inst)
 
Toshiaki Nakayama
No Relationships to Disclose
 
Yasuhiko Sakata
No Relationships to Disclose
 
Sadamoto Zenda
Consulting or Advisory Role - AYUMI; Maruho
Speakers' Bureau - Bristol-Myers Squibb; Merck
 
Hironobu Hashimoto
No Relationships to Disclose